News articles about Novavax (NASDAQ:NVAX) have been trending somewhat positive on Monday, according to Accern. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Novavax earned a media sentiment score of 0.07 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 46.9097707867825 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the media stories that may have impacted Accern Sentiment’s analysis:
Novavax (NASDAQ NVAX) remained flat at $$1.43 during trading on Monday. 5,026,213 shares of the company traded hands, compared to its average volume of 5,964,526. Novavax has a twelve month low of $0.73 and a twelve month high of $1.78. The company has a debt-to-equity ratio of -4.28, a current ratio of 3.31 and a quick ratio of 3.31.
Novavax (NASDAQ:NVAX) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.01. The business had revenue of $8.35 million during the quarter, compared to analysts’ expectations of $6.42 million. Novavax had a negative return on equity of 787.38% and a negative net margin of 726.35%. The business’s revenue was up 158.5% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.24) earnings per share. sell-side analysts anticipate that Novavax will post -0.62 EPS for the current fiscal year.
Several brokerages recently weighed in on NVAX. BidaskClub cut Novavax from a “buy” rating to a “hold” rating in a research report on Saturday. Seaport Global Securities reiterated a “neutral” rating on shares of Novavax in a research report on Friday, October 6th. Zacks Investment Research cut Novavax from a “hold” rating to a “sell” rating in a research report on Thursday, November 16th. Cantor Fitzgerald reiterated a “hold” rating and set a $2.00 price target on shares of Novavax in a research report on Wednesday, November 8th. Finally, Citigroup upgraded Novavax from a “neutral” rating to a “buy” rating and set a $2.00 price target for the company in a research report on Tuesday, October 31st. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the company’s stock. Novavax presently has an average rating of “Hold” and an average target price of $3.12.
In other Novavax news, insider Stanley C. Erck acquired 100,000 shares of the business’s stock in a transaction dated Thursday, November 9th. The stock was acquired at an average cost of $1.13 per share, for a total transaction of $113,000.00. Following the completion of the transaction, the insider now directly owns 228,279 shares of the company’s stock, valued at $257,955.27. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 4.00% of the stock is owned by insiders.
ILLEGAL ACTIVITY WARNING: “Novavax (NASDAQ:NVAX) Earns Daily Coverage Optimism Score of 0.07” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/12/04/novavax-nvax-receives-daily-news-sentiment-score-of-0-07.html.
Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.
Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.